Clinical trials: 2019-nCoV
Healthy Volunteers
A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
The purpose of this study is to learn about the safety and tolerability of different doses of REGN17092 administered with a needle either under the skin (called "subcutaneous") or into a vein (called an "infusion") in healthy…
- Trial name
- NCT05923424
- Testing
- REGN17092
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Coronavirus Disease 2019
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Popular topic：Clinical study of recombinant Novel Coronavirus vaccine (CHO cell) combined with influenza vaccine. Research purpose:Main purpose:To evaluate the immunogenicity of recombinant Novel Coronavirus vaccine (CHO cells)…
- Trial name
- NCT05107375
- Testing
- Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Covid-19, Coronavirus Disease 2019
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled, trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bempegaldesleukin (BEMPEG; NKTR-214) in…
- Trial name
- NCT04646044
- Testing
- Bempegaldesleukin, Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nektar Therapeutics
Coronavirus Infection
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.
- Trial name
- NCT04442230
- Testing
- NasoVAX
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Altimmune, Inc.
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza health-related outcomes of people with COVID-19 or influenza the effects of vaccines in people with COVID-19 or influenza.
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT06163677
- Testing
- COVID-19 Vaccine
- Sponsor
- Pfizer
Covid-19, Protection Against COVID-19
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was skipped due to changes in the overall clinical development plan.
- Trial name
- NCT04537949
- Testing
- BNT162b3
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Biological Availability, Healthy Participants
A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants
Medicines that may have different names or be made in different ways but have the same effect on the body are called bioequivalent.
- Trial name
- NCT06397144
- Testing
- Paxlovid, Nirmatrelvir/ritonavir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration The secondary objectives of the study are: To assess the safety…
- Trial name
- NCT04992273
- Testing
- casirivimab+imdevimab
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Regeneron Pharmaceuticals
Coronavirus Disease (COVID-19)
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection.
- Trial name
- MOVe-AHEAD (NCT04939428)
- Testing
- Molnupiravir
- Where
- 226 sites in United States, Argentina and 21 more
- Volunteers
- 2,441 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Covid19
Sotrovimab Expanded Access Treatment Protocol (COVID-19)
An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.
- Trial name
- NCT05235347
- Testing
- Sotrovimab
- Where
- 4 sites in United States
- Sponsor
- Vir Biotechnology, Inc.
Covid19, SARS-CoV2 Infection
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.
- Conditions
- Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019
- Trial name
- NCT05047783
- Testing
- Masitinib Mesylate
- Where
- 6 sites in France, Russia and 1 more
- Volunteers
- 78 people
- Sponsor
- AB Science
COVID-19
Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)
This study is a prospective, single center, observational, cohort study of patients to (1) describe the kinetics and temporal relationship of changes in eicosanoid and cytokine mediators in patients with severe COVID-19 admitted…
- Trial name
- NCT04452942
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- EicOsis Human Health Inc.
COVID-19
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
- Trial name
- NCT05787418
- Testing
- HH-120 Nasal Spray
- Where
- 2 sites in China
- Volunteers
- 918 people
- Sponsor
- Huahui Health
Healthy Participants
A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.
The purpose of this Phase 1 clinical trial is to help us understand how the drug is changed and eliminated from your body after you take it, the safety, and the the extent to which dise effects can be tolerated of PF-07321332…
- Trial name
- NCT05339334
- Testing
- PF-07321332/ritonavir
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infection of Upper Respiratory Tract Caused by 2019-nCoV
SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
Evaluating the efficacy and safety of SA55 injection in light/medium COVID-19 patients
- Trial name
- NCT06042764
- Testing
- SA55 Injection
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
This master protocol serves as a common reference for the inpatient and outpatient clinical studies that share common elements.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077332
- Testing
- Famotidine, Celecoxib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
COVID-19, Pneumonia
A Study of LY3127804 in Participants With COVID-19
A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants who are hospitalized with pneumonia and presumed or confirmed COVID-19.
- Trial name
- NCT04342897
- Testing
- LY3127804
- Where
- 13 sites in United States
- Volunteers
- 95 people
- Sponsor
- Eli Lilly and Company
SARS-CoV-2 Infection, COVID-19
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
This was an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to…
- Trial name
- NCT05541861
- Testing
- BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg
- Where
- 17 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
eVusheld Assessment reaL wORld Effectiveness in DoD Health System
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR DoD (NCT05569408)
- Testing
- EVUSHELD
- Where
- United States
- Volunteers
- 4,724 people
- Sponsor
- AstraZeneca